New search Hide text from Guidelines
C CARDIOVASCULAR SYSTEMThis group comprises substances used for the treatment of cardiovascular conditions.
Drugs used for the treatment of hypertension are classified in C02 - Antihypertensives, C03 - Diuretics, C07 - Beta blocking agents, C08 - Calcium channel blockers, and C09 - Agents acting on the renin-angiotensin system. For the classification of combination products of antihypertensives from different ATC groups, the following ranking should be used, from higher to lower precedence: C09, C07, C08, and C03.
C03 DIURETICS
This group comprises diuretics, plain and in combination with potassium or other agents. Vasopressin antagonists are also included in this group. Potassium-sparing agents are classified in C03D and C03E.
Combinations with digitalis glycosides, see C01AA.
Combinations with antihypertensives, see C02L - Antihypertensives and diuretics in combination.
Combinations with beta blocking agents, see C07B - C07D.
Combinations with calcium channel blockers, see C08.
Combinations with agents acting on the renin angiotensin system, see C09B and C09D.
| The DDDs for diuretics are based on monotherapy. Most diuretics are used both for the treatment of edema and hypertension in similar doses and the DDDs are therefore based on both indications. The DDDs for combinations correspond to the DDD for the diuretic component, except for ATC group C03E, see comments under this level. |
C03D ALDOSTERONE ANTAGONISTS AND OTHER POTASSIUM-SPARING AGENTS
C03DA Aldosterone antagonists
Finerenone indicated for chronic kidney disease is classified in this group.
| The DDD for finerenone is based on the treatment of chronic kidney disease associated with type 2 diabetes. |
| ATC code | Name | DDD | U | Adm.R | Note |
| C03DA01 | spironolactone | 75 | mg | O | |
| C03DA02 | potassium canrenoate | 0.4 | g | P | |
| C03DA03 | canrenone | ||||
| C03DA04 | eplerenone | 50 | mg | O | |
| C03DA05 | finerenone | 20 | mg | O |
Last updated: 2024-01-26